In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reimbursement Delays: Still Variable, Getting Even More So

Executive Summary

The EU enlargement project may have just taken a big step forward, but when it comes to harmonization, there's still work to do. One of the most challenging aspects to doing business in Europe for pharma firms remains the complex and lengthy pricing and reimbursement negotiations required in each market in order to get drugs to patients. Despite EU guidelines limiting the reimbursement delay period to 180 days, half of the "old" EU member states still take far longer, according to data from Cambridge Pharma Consultancy (part of IMS Health).





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts